Author: Waterer, Grant W; Rello, Jordi; Waterer, Grant W.
Title: Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. Cord-id: qbf689u2 Document date: 2020_9_16
ID: qbf689u2
Snippet: COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but
Document: COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available.
Search related documents:
Co phrase search for related documents- absolute difference and adjunctive therapy: 1
- absolute difference and long follow: 1, 2
- absolute difference and lymphocyte count: 1, 2
- academic commercial and access open: 1
- acute condition and lymphocyte count: 1, 2
- adjunctive therapy and long follow: 1, 2
- adjunctive therapy and long outcome: 1
- long follow and lymphocyte count: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date